Latest Earnings Results: Q3 '26
Estimated EPS
-$0.79
Reported EPS
-$0.60
Surprise
+23.69%
Estimated Rev
$0M
Reported Rev
---
Surprise
---
Reported GAAP EPS of -$0.60 down -130.77% YoY
Bullish Takeaway
Belite Bio's DRAGON trial met its primary endpoint, with a 35.7% reduction in retinal-lesion growth versus placebo; tinlarebant received FDA Priority Review and Japan's Sakigake designation.
Bearish Takeaway
Belite Bio's Q3 expenses were higher than Q3 2025 levels, its net loss was higher than in Q3 2025, and PHOENIX results may not support regulatory approval; FDA review is still ongoing.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | -$0.86 | -- | -- | N/A |
Q3 '26 | -$0.79 | -$0.60 | 23.69% | BEAT |
Q2 '26 | -$0.78 | -$0.70 | 9.88% | BEAT |
Q1 '26 | -$0.63 | -$0.34 | 46.45% | BEAT |
Q4 '25 | -$0.55 | -$0.38 | 30.43% | BEAT |